Use of FDG PET/CT for investigation of febrile neutropenia: Evaluation in high-risk cancer patients

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 8, 2012, Pages 1348-1355

  Guy, Stephen D ^a,b   Tramontana, Adrian R ^a,b   Worth, Leon J ^c   Lau, Eddie ^c   Hicks, Rodney J ^c   Seymour, John F ^c   Thursky, Karin A ^c   Slavin, Monica A ^c  

^a Western Health ^*  (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

FDG PET CT; Febrile neutropenia

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BODY TEMPERATURE; CANCER RISK; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEBRILE NEUTROPENIA; FEMALE; HIGH RISK PATIENT; HUMAN; MALE; NEUTROPHIL COUNT; PROSPECTIVE STUDY;

ADULT; AGED; FEMALE; FEVER; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RISK;

EID: 84865500508     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2143-7     Document Type: Article

References (17)

1. HughesWT, ArmstrongD, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-51. (Pubitemid 34194843)
2. Pizzo PA. Management offever in patients with cancer and treatment-induced neutropenia. N Engl J Med. 1993;328:1323-32.
3. Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006;57:176-89. (Pubitemid 43160156)
4. Ruhnke M, Bohme A, Buchheidt D, Cornely O, Donhuijsen K, Einsele H, et al. Diagnosis ofinvasive fungal infections in hematology and oncology -guidelines from the Infectious DiseasesWorking Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). Ann Oncol. 2012;23:823-33.
5. Einsele H, Loeffler J. Contribution of new diagnostic approaches to antifungal treatment plans in high-risk haematology patients. Clin Microbiol Infect. 2008;14 Suppl 4:37-45. (Pubitemid 351593915)
6. Barnes PD, Marr KA. Risks, diagnosis and outcomes ofinvasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol. 2007;139(4):519-31. (Pubitemid 350043811)
7. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996;23(10):1409-15. (Pubitemid 26340597)
8. Bleeker-Rovers CP, Vos FJ, Corstens FH, Oyen WJ. Imaging ofinfectious diseases using [18F]fluorodeoxyglucose PET. Q J Nucl Med Mol Imaging. 2008;52(1):17-29. (Pubitemid 351351041)
9. Mahfouz T, Miceli MH, Saghafifar F, Stroud S, Jones-Jackson L, Walker R, et al. 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management ofinfections in patients with multiple myeloma: a study of 165 infectious episodes. J Clin Oncol. 2005;23 (31):7857-63. (Pubitemid 46661462)
10. Miceli MH, Jones-Jackson LB, Walker RC, Talamo G, Barlogie B, Anaissie EJ. Diagnosis ofinfection ofimplantable central venous catheters by [18F]fluorodeoxyglucose positron emission tomography. Nucl Med Commun. 2004;25(8):813-8. (Pubitemid 39099994)
11. Miceli M, Atoui R, Walker R, Mahfouz T, Mirza N, Diaz J, et al. Diagnosis of deep septic thrombophlebitis in cancer patients by fluorine-18 fluorodeoxyglucose positron emission tomography scanning: a preliminary report. J Clin Oncol. 2004;22:1949-56. (Pubitemid 41095188)
12. Ho AY, Pagliuca A, Maisey MN, Mufti GJ. Positron emission scanning with 18-FDG in the diagnosis of deep fungal infections. Br J Haematol. 1998;101(2):392-3. (Pubitemid 28261134)
13. Hot A, Maunoury C, Poiree S, Lanternier F, Viard JP, Loulergue P, et al. Diagnostic contribution of the positron emission scanning with 18F-FDG for invasive fungal infections. Clin Microbiol Infect. 2011;17:409-17.
14. Xu B, Shi P,Wu H, Guo X,WangQ, Zhou S. Utility of FDGPET/CT in guiding antifungal therapy in acute leukemia patients with chronic disseminated candidiasis. Clin Nucl Med. 2010;35(8):567-70.
15. Connell CA, Corry J, Milner AD, Hogg A, Hicks RJ, Rischin D, et al. Clinical impact of, prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck. 2007;29(11):986-95.
16. Bleeker-Rovers CP, Vos FJ, van der Graaf WT, Oyen WJ. Nuclear medicine imaging ofinfection in cancer patients (with emphasis on FDG-PET). Oncologist. 2011;16(7):980-91.
17. Ruf J, Oeser C, Amthauer H. Clinical role of anti-granulocyte MoAb versus radiolabeled white blood cells. Q J Nucl Med Mol Imaging. 2010;54(6):599-616.